Valuation + financial yield expert for pathfinder-led, IP-backed life sciences and at-risk innovation.

Sharpen pioneers on the 3rd to 6th dimension of their mission.

Actionable value intelligence

Backing what's uncertain. Operating it. Funding it. Making it happen (anyway).

Every pioneer's context differs (science, stage, cap table), yet the same challenges repeat. And value trajectory is among the hardest things to structure AND convey.

Financing, partnering, exit, accounting, reporting. Gaining altitude there takes context clarity, and a sharp, long view. We work these ascents, north face included.

We´re fair on 2 counts: innovative potential, and the capacity to build alignment around it.

Gaining altitude on the value of innovation: the next 4 dimensions to aim and reach.

Innovative ventures are on a mission. Easily said. In practice, the ones effectively on track go 4 dimensions beyond the crowd. That's where we sharpen the read.

3rd — Long-game
No high-level athlete treats a career as a short game. Life sciences innovation is a long chain of transitions, from idea to adoption, from idea to yield, where every number-related decision fortifies (or erodes) a value trajectory. Readiness for the long game is part of the read.

4th — Legible to non-peers
Pioneers are held accountable, but they think and tick differently than most. How to translate value into a framework others can seize? Boards need it, because their role is to question. Auditors and institutional players expect it but rely on hard frameworks. Big stretches.

5th — Value AND realization
The instinct is to focus on one, which mostly falls short. Because pioneering is a marathon of internal and external shocks. A value trajectory only unfolds if both are steered together.

6th — It´s lonely at this altitude
Whoever goes there needs a place to pause, reflect, and be challenged just enough to gain readiness for the next level.

"From financing to deal making.

From decision making to accounting.

Generating and maximizing options.

It is a strategic framework."

The investor perspective

First-time pathfinders are often surprised by the importance we give to the investor perspective. Whoever backs an asset before the market has learned to price it, is taking on exposure.

Science and capital rarely come from the same pocket

The breakthrough is one thing. Funding it — through early investors, VCs, family offices, or industrial partner — is another. The asset moves between them, and each reads it differently.

Understanding what yield requires

Valuing an asset is one skill. Understanding what each type of investor actually needs under uncertainty — their return logic, their expectation on optionality, their constraints — is another. Rarely found in the same place.

Making each side legible to the other

The intersection where we work: the science made legible to the capital that funds it, the capital logic made legible to the team that built it — so neither side goes unheard in a language that was never theirs to begin with.

Discover our financial and valuation services

Think about what you need most

To articulate value over the long game.

Number that holds

Fair value, independent opinion, accounting valuation.

IFRS. US GAAP. HGB. Transfer Price. IP Value.

When the standard must be applied with precision and the reasoning must survive audit.
→ Fair Value

Decision that holds

Value for Decision Makers.

When the asset is strong and the financial narrative is not yet.

When the room needs to reach a conclusion and the parties don't yet speak the same language.

→ Value for Decision Makers

New to this

Incubators - First timers

When you sense there is more to learn

When a 1:1 crossing silos from science to finance, through deal making and legal realities — would change what you build.

→ Workshop & Mentoring

Deal value that holds

High stake - Very contingent

When control will partially escape you and the terms need to carefully be thought through.

When this move closes others.

→ Special Events

20y+ in the intimacy of pioneers´complexity and innovation uncertainty

Since the biotech era began, we've focused on value perception and decision-making at the most uncertain moments of innovative assets: early-stage and exit deals.

What it means for the parties, why they engage, or withdraw. How to evidence and measure not only value, but value trajectory. Why price can differ so much from value in this field. And, most critically: what makes pathfinders and pioneers aim, and reach.

Because we’ve been there from the earliest stage, through every financing, partnering and exit step along the way (and biotech fair value accounting bizarreries!), our read is one of the most longitudinal and context-guided in the field.